Korro Bio, Inc. financial data

Symbol
KRRO on Nasdaq
Industry
Pharmaceutical Preparations
Location
60 First Street, 2 Nd Floor, Suite 250, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Frequency Therapeutics, Inc. (to 11/6/2023)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1K % +114%
Return On Equity -61.4 % -182%
Return On Assets -47.7 % +8.01%
Operating Margin -925 % -655%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.3M shares -74.5%
Common Stock, Shares, Outstanding 9.28M shares -74.2%
Entity Public Float 12.1M USD -74%
Common Stock, Value, Issued 9K USD -75%
Weighted Average Number of Shares Outstanding, Basic 8.99M shares +3150%
Weighted Average Number of Shares Outstanding, Diluted 8.99M shares +3150%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 60.1M USD +40%
General and Administrative Expense 31.5M USD +215%
Operating Income (Loss) -91.6M USD -73%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -85.3M USD -68.5%
Income Tax Expense (Benefit) 47K USD +104%
Net Income (Loss) Attributable to Parent -85.3M USD -68.5%
Earnings Per Share, Basic 78.1 USD/shares +96.2%
Earnings Per Share, Diluted 78.1 USD/shares +96.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 91.2M USD +130%
Marketable Securities, Current 66.3M USD
Other Assets, Current 255K USD +37.8%
Assets, Current 164M USD +238%
Property, Plant and Equipment, Net 24.7M USD +1762%
Operating Lease, Right-of-Use Asset 24.8M USD -10.4%
Other Assets, Noncurrent 2.67M USD
Assets 250M USD +214%
Accounts Payable, Current 5.69M USD +340%
Employee-related Liabilities, Current 1.87M USD -43.8%
Accrued Liabilities, Current 6.18M USD +26.8%
Liabilities, Current 12.3M USD +48%
Operating Lease, Liability, Noncurrent 38M USD +48.2%
Other Liabilities, Noncurrent 1.18M USD
Liabilities 51.5M USD +51.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 21K USD
Retained Earnings (Accumulated Deficit) -224M USD +23.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 198M USD
Liabilities and Equity 250M USD +214%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.9M USD -11.2%
Net Cash Provided by (Used in) Financing Activities 139K USD -99.7%
Net Cash Provided by (Used in) Investing Activities -5.61M USD -136%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 9.28M shares -74.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -27.4M USD -166%
Deferred Tax Assets, Valuation Allowance 146M USD +304%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 153M USD +312%
Operating Lease, Liability 38.5M USD
Depreciation 3.55M USD +36.7%
Payments to Acquire Property, Plant, and Equipment 5.61M USD +271%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.8M USD -23.5%
Lessee, Operating Lease, Liability, to be Paid 69.7M USD
Property, Plant and Equipment, Gross 34M USD +270%
Operating Lease, Liability, Current 457K USD -78.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.34M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 6.25M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 31.2M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.56M USD
Deferred Tax Assets, Operating Loss Carryforwards 80.4M USD +311%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.56M USD +61.8%
Additional Paid in Capital 422M USD +25.2%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments Due, Next Twelve Months 4.27M USD +2.69%
Deferred Tax Assets, Net of Valuation Allowance 7.72M USD +587%
Share-based Payment Arrangement, Expense 3.46M USD +141%
Operating Leases, Future Minimum Payments, Due in Three Years 4.4M USD -0.23%
Operating Leases, Future Minimum Payments Due 40.2M USD -9.56%
Interest Expense 596K USD -28.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%